ECC 2015: New survival data from the Combi-v trial investigating a combination of two targeted therapies in melanoma

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with unresectable or metastatic BRAF V600E/K mutation-positive cut... Author: EMJ Added: 10/05/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts